|

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma

RECRUITINGPhase 2/3Sponsored by West China Hospital
Actively Recruiting
PhasePhase 2/3
SponsorWest China Hospital
Started2025-05-02
Est. completion2026-06-30
Eligibility
Age1 Month – 4 Years
Healthy vol.Accepted

Summary

The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).

Eligibility

Age: 1 Month – 4 YearsHealthy volunteers accepted
Inclusion Criteria:

1. all patients with ulcer IH;
2. children with ulcer IH treated with propranolol.

Exclusion Criteria:

1\) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons.

\-

Conditions2

CancerInfantile Hemangioma

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.